首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD27BP |
| Uniprot No | O15304 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-175aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMPKRSCP FADVAPLQLK VRVSQRELSR GVCAERYSQE VFEKTKRLLF LGAQAYLDHV WDEGCAVVHL PESPKPGPTG APRAARGQML IGPDGRLIRS LGQASEADPS GVASIACSSC VRAVDGKAVC GQCERALCGQ CVRTCWGCGS VACTLCGLVD CSDMYEKVLC TSCAMFET |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD27/CD70(CD27BP)重组蛋白研究的3篇参考文献摘要(注：CD27BP通常指CD70.即CD27的配体)：
---
1. **文献名称**: *CD70 as a target for cancer immunotherapy*
**作者**: Buchan SL et al.
**摘要**: 研究探讨了CD70-CD27信号通路在肿瘤免疫逃逸中的作用，并开发了重组人源化抗CD70抗体。实验表明，阻断CD70可抑制肿瘤生长并增强T细胞抗肿瘤活性，为癌症免疫治疗提供新策略。
---
2. **文献名称**: *Recombinant CD27L (CD70) enhances T cell activation and anti-tumor immunity*
**作者**: Lens SM et al.
**摘要**: 通过体外表达重组CD70蛋白，验证其与CD27结合后促进T细胞增殖和细胞因子分泌的能力，证明其在增强抗肿瘤免疫应答中的潜在应用价值。
---
3. **文献名称**: *Structural and functional characterization of the CD27-CD70 complex*
**作者**: van Oosterwijk MF et al.
**摘要**: 利用重组CD27和CD70蛋白进行结构解析和功能研究，揭示了二者相互作用的关键表位，为开发靶向该通路的抑制剂或激动剂提供了分子基础。
---
注：CD27BP相关研究多集中于其配体CD70(即CD27L)，上述文献聚焦于其结构、功能及治疗应用。如需具体文献来源，建议通过PubMed或Google Scholar检索更新进展。
CD27BP, also known as CD70. is a type II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) superfamily. It serves as the natural ligand for CD27. a co-stimulatory receptor expressed on T cells, B cells, and natural killer (NK) cells. The CD27-CD70 interaction plays a pivotal role in regulating adaptive immune responses, including T-cell activation, differentiation, and memory formation, as well as B-cell antibody production. Dysregulation of this pathway has been implicated in autoimmune diseases, chronic inflammation, and cancer immune evasion.
Recombinant CD27BP proteins are engineered to mimic the extracellular domain of native CD70. often fused with Fc regions or tags (e.g., His-tag) to enhance solubility and purification efficiency. These proteins are typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, particularly glycosylation, which is critical for receptor binding and functional activity.
In research, recombinant CD27BP is utilized to study CD27 signaling mechanisms, immune synapse formation, and lymphocyte modulation. Therapeutically, it has dual applications: as an agonist to amplify anti-tumor immunity in cancer immunotherapy (e.g., enhancing CAR-T cell efficacy) or as a blocking agent to inhibit pathological immune activation in autoimmune disorders. Recent studies also explore its potential as a vaccine adjuvant to boost memory T-cell responses. However, challenges remain in balancing its immune-stimulatory effects with risks of cytokine storms or unintended immunosuppression. Current clinical trials are investigating CD27BP-targeting biologics, including monoclonal antibodies and recombinant fusion proteins, for hematologic malignancies and solid tumors.
×
